277 related articles for article (PubMed ID: 24093809)
1. Participant experiences and facilitators and barriers to pill use among men who have sex with men in the iPrEx pre-exposure prophylaxis trial in San Francisco.
Gilmore HJ; Liu A; Koester KA; Amico KR; McMahan V; Goicochea P; Vargas L; Lubensky D; Buchbinder S; Grant R
AIDS Patient Care STDS; 2013 Oct; 27(10):560-6. PubMed ID: 24093809
[TBL] [Abstract][Full Text] [Related]
2. Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand.
Tangmunkongvorakul A; Chariyalertsak S; Amico KR; Saokhieo P; Wannalak V; Sangangamsakun T; Goicochea P; Grant R
AIDS Care; 2013 Aug; 25(8):961-7. PubMed ID: 23252473
[TBL] [Abstract][Full Text] [Related]
3. Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study).
King HL; Keller SB; Giancola MA; Rodriguez DA; Chau JJ; Young JA; Little SJ; Smith DM
AIDS Behav; 2014 Sep; 18(9):1722-5. PubMed ID: 25017425
[TBL] [Abstract][Full Text] [Related]
4. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis.
Marcus JL; Glidden DV; Mayer KH; Liu AY; Buchbinder SP; Amico KR; McMahan V; Kallas EG; Montoya-Herrera O; Pilotto J; Grant RM
PLoS One; 2013; 8(12):e81997. PubMed ID: 24367497
[TBL] [Abstract][Full Text] [Related]
5. FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis.
Corneli AL; Deese J; Wang M; Taylor D; Ahmed K; Agot K; Lombaard J; Manongi R; Kapiga S; Kashuba A; Van Damme L;
J Acquir Immune Defic Syndr; 2014 Jul; 66(3):324-31. PubMed ID: 25157647
[TBL] [Abstract][Full Text] [Related]
6. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Jan; 60(3):65-8. PubMed ID: 21270743
[TBL] [Abstract][Full Text] [Related]
7. Reactions and Receptivity to Framing HIV Prevention Message Concepts About Pre-Exposure Prophylaxis for Black and Latino Men Who Have Sex with Men in Three Urban US Cities.
Mimiaga MJ; Closson EF; Battle S; Herbst JH; Denson D; Pitts N; Holman J; Landers S; Mansergh G
AIDS Patient Care STDS; 2016 Oct; 30(10):484-489. PubMed ID: 27749110
[TBL] [Abstract][Full Text] [Related]
8. HIV preexposure prophylaxis: new data and potential use.
Celum CL
Top Antivir Med; 2011 Dec; 19(5):181-5. PubMed ID: 22298887
[TBL] [Abstract][Full Text] [Related]
9. Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.
Plosker GL
Drugs; 2013 Mar; 73(3):279-91. PubMed ID: 23444256
[TBL] [Abstract][Full Text] [Related]
10. Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers.
Mutua G; Sanders E; Mugo P; Anzala O; Haberer JE; Bangsberg D; Barin B; Rooney JF; Mark D; Chetty P; Fast P; Priddy FH
PLoS One; 2012; 7(4):e33103. PubMed ID: 22511916
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.
Liegler T; Abdel-Mohsen M; Bentley LG; Atchison R; Schmidt T; Javier J; Mehrotra M; Eden C; Glidden DV; McMahan V; Anderson PL; Li P; Wong JK; Buchbinder S; Guanira JV; Grant RM;
J Infect Dis; 2014 Oct; 210(8):1217-27. PubMed ID: 24740633
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.
Okwundu CI; Uthman OA; Okoromah CA
Cochrane Database Syst Rev; 2012 Jul; (7):CD007189. PubMed ID: 22786505
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States.
Grohskopf LA; Chillag KL; Gvetadze R; Liu AY; Thompson M; Mayer KH; Collins BM; Pathak SR; Oʼhara B; Ackers ML; Rose CE; Grant RM; Paxton LA; Buchbinder SP
J Acquir Immune Defic Syndr; 2013 Sep; 64(1):79-86. PubMed ID: 23466649
[TBL] [Abstract][Full Text] [Related]
14. Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men.
Marcus JL; Glidden DV; McMahan V; Lama JR; Mayer KH; Liu AY; Montoya-Herrera O; Casapia M; Hoagland B; Grant RM
PLoS One; 2014; 9(3):e91513. PubMed ID: 24637511
[TBL] [Abstract][Full Text] [Related]
15. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
Myers GM; Mayer KH
AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497
[TBL] [Abstract][Full Text] [Related]
16. Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial.
Kibengo FM; Ruzagira E; Katende D; Bwanika AN; Bahemuka U; Haberer JE; Bangsberg DR; Barin B; Rooney JF; Mark D; Chetty P; Fast P; Kamali A; Priddy FH
PLoS One; 2013; 8(9):e74314. PubMed ID: 24086333
[TBL] [Abstract][Full Text] [Related]
17. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
Mugwanya KK; Wyatt C; Celum C; Donnell D; Mugo NR; Tappero J; Kiarie J; Ronald A; Baeten JM;
JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343
[TBL] [Abstract][Full Text] [Related]
18. HPTN 083-02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study.
Psaros C; Goodman GR; Lee JS; Rice W; Kelley CF; Oyedele T; Coelho LE; Phanuphak N; Singh Y; Middelkoop K; Griffith S; McCauley M; Rooney J; Rinehart AR; Clark J; Go V; Sugarman J; Fields SD; Adeyeye A; Grinsztejn B; Landovitz RJ; Safren SA;
J Int AIDS Soc; 2024 May; 27(5):e26252. PubMed ID: 38783534
[TBL] [Abstract][Full Text] [Related]
19. Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions.
Donnell D; Hughes JP; Wang L; Chen YQ; Fleming TR
J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S130-4. PubMed ID: 23764624
[TBL] [Abstract][Full Text] [Related]
20. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
Celum C; Morrow RA; Donnell D; Hong T; Hendrix CW; Thomas KK; Fife KH; Nakku-Joloba E; Mujugira A; Baeten JM;
Ann Intern Med; 2014 Jul; 161(1):11-9. PubMed ID: 24979446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
